Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
Clinical trial NCT03160521 · COMPLETED
Trial details
- NCT number
- NCT03160521
- Sponsor
- Rovi Pharmaceuticals Laboratories
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-02
- Primary completion
- 2018-12-17
- Enrollment
- 438
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.